clinical trial · NCT05075824
A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
Hoffmann-La Roche·phase2·completed·n = 95
Sickle Cell DiseaseCrovalimabPlacebo
brief summary
This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.
started
Mar 9, 2022
primary completion
Jun 11, 2025
completion
Apr 9, 2026
last updated
Apr 16, 2026
official title
A Randomized Double-Blind Phase IIA Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol